NASHVILLE, Tenn.–(Business enterprise WIRE)–Harrow Wellness, Inc. (NASDAQ: HROW), an eyecare pharmaceutical business concentrated on the improvement, output, sale, and distribution of revolutionary ophthalmic prescription medicines, currently declared success for the second quarter ended June 30, 2022. The Company also posted its second quarter Letter to Stockholders and company presentation to the “Investors” portion of its site, harrowinc.com.

“We are pleased with equally our money and operational overall performance for the duration of the next quarter of 2022,” claimed Mark L. Baum, CEO of Harrow Health. “The 2nd quarter was our eighth consecutive quarter of document benefits in a lot of of the money metrics that we observe, including whole revenues, income for each shipping and delivery working day, and full amount of product models dispersed. From an operational viewpoint, through the quarter, we ongoing to aim on guaranteeing that the Harrow eyecare system has the infrastructure, programs, resources, and expertise essential to execute on the growth that we be expecting in our compounded pharmaceutical organization and new and even more dramatic expansion we be expecting from the ongoing integration of Fda-permitted branded pharmaceutical solutions into the Harrow system.

“Our business continues to be robust, and we believe that the 2nd half of 2022 will be a extremely consequential time period for Harrow. We be expecting several milestone activities in the course of the next 50 %, such as the PDUFA target motion day for AMP-100, a patented ocular floor anesthetic drug applicant, as nicely as various item launches of compounded formulations. In addition, we proceed to be tough at get the job done making an attempt to close transactions, which are at various levels of completion, that we strongly believe will include benefit to our corporation in various vital approaches.”

2nd quarter figures of merit: